Cas No.: | 104121-92-8 |
Chemical Name: | 1,3-Cyclohexanediol,2-(3-hydroxypropoxy)-4-methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R)-5-hydroxy-1,5-dimethylhexyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-,(1R,2R,3R,5Z)- |
Synonyms: | 1,3-Cyclohexanediol,2-(3-hydroxypropoxy)-4-methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R)-5-hydroxy-1,5-dimethylhexyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-,(1R,2R,3R,5Z)-;Eldecalcitol;(1S,2S,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-(3-hydroxypropoxy)-4-methylidenecyclohexane-1,3-diol;1,3-Cyclohexanediol,2-(3-hydroxypropoxy)-4-methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R)-5-hydroxy-1,5-dimethylhexyl]-7;1α,25-dihydroxy-2β-(3-hydroxypropoxy)Vitamin D3;2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3;CS-0363;ED 71;ED-71;HY-A0020;UNII-I2JP8UE90H;2-(3-Hydroxypropoxy)-1,25-dihydroxyvitamin D3;Eldecalcitol(ED-71);2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3;1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3;2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitaMin D3;(1R,Z)-5-((E)-2-((1R,7aR)-1-((R)-6-hydroxy-6-methylheptan-2-yl)-7a-methylhexahydro-1H-inden-4(2H)-ylidene)ethylidene)-2-(3-hydroxypropoxy)-4-methylenecyclohexane-1,3-diol |
SMILES: | CC(C)(O)CCC[C@@H](C)[C@H]([C@]1(CCC/2)C)CC[C@@]1([H])C2=C\C=C3C[C@H](O)[C@H](OCCCO)[C@@H](O)C\3=C |
Formula: | C30H50O5 |
M.Wt: | 490.715010166168 |
Purity: | >99% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Eldecalcitol (ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3) is an analog of 1,25-dihydroxyvitamin D3 that improves bone mineral density.Eldecalcitol (ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3) is more efficacious than alfacalcidol in preventing vertebral and wrist fractures in osteoporotic patients with vitamin D sufficiency, with a safety profile similar to alfacalcidol. |
Target: | Vd analog |
References: | [1]. Matsumoto T.Osteoporosis Treatment by a New Active Vitamin D3 Compound, Eldecalcitol, in Japan.Curr Osteoporos Rep. 2012 Aug 24. [2]. Shiraki M, et al. Eldecalcitol normalizes bone turnover markers regardless of their pre-treatment levels.Curr Med Res Opin. 2012 Aug 23. [3]. Matsumoto T, Endo I.Eldecalcitol for the treatment of osteoporosis.Drugs Today (Barc). 2012 Mar;48(3):189-96. [4]. Sakai S, et al.Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength.Bone. 2012 May;50(5):1054-63. Epub 2012 Feb 17. [5]. Sanford M, McCormack PL.Spotlight on eldecalcitol in osteoporosis.Drugs Aging. 2012 Jan 1;29(1):69-71. |